Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest SABBY MANAGEMENT, LLC Stock Portfolio

$148Billion– No. of Holdings #27

SABBY MANAGEMENT, LLC Performance:
2024 Q2: -11.58%YTD: -34.21%2023: -61.78%

Performance for 2024 Q2 is -11.58%, and YTD is -34.21%, and 2023 is -61.78%.

About SABBY MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, SABBY MANAGEMENT, LLC reported an equity portfolio of $148.7 Billions as of 30 Jun, 2024.

The top stock holdings of SABBY MANAGEMENT, LLC are VANI, , RDHL. The fund has invested 1.8% of it's portfolio in VIVANI MEDICAL INC and 0.5% of portfolio in CORE SCIENTIFIC.

The fund managers got completely rid off TONIX PHARMACEUTICALS HLDG (TNXP), GLOBAL MOFY METAVERSE LTD and RECON TECHNOLOGY LTD (RCON) stocks. They significantly reduced their stock positions in CHINA NATURAL RESOURCES INC (CHNR), ELTEK LTD and REDHILL BIOPHARMA LTD (RDHL). SABBY MANAGEMENT, LLC opened new stock positions in CORE SCIENTIFIC, GREENWAVE TECHNOLOGY (GWAV) and ISHARES TR (IJR). The fund showed a lot of confidence in some stocks as they added substantially to LIPELLA PHARMACEUTICALS INC (LIPO), ENSYSCE BIOSCIENCES INC (ENSC) and BIOVIE INC (BIVI).
SABBY MANAGEMENT, LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2024

SABBY MANAGEMENT, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that SABBY MANAGEMENT, LLC made a return of -11.58% in the last quarter. In trailing 12 months, it's portfolio return was -64.8%.

New Buys

Ticker$ Bought
core scientific762,073,000
greenwave technology406,165,000
ishares tr304,335,000
reviva pharmaceutcls hldgs inc303,356,000
sonnet biotherapeutics hldng inc223,495,000
aptevo therapeutics inc153,459,000
avenue therapeutics inc130,879,000
effector therapeutics102,140,000

New stocks bought by SABBY MANAGEMENT, LLC

Additions to existing portfolio by SABBY MANAGEMENT, LLC

Reductions

Ticker% Reduced
china natural resources inc-75.55
eltek ltd-64.1
redhill biopharma ltd-42.17
wearable devices ltd-38.93
gevo inc-28.57
vivani medical inc-20.46
neximmune inc-16.62
inmed pharmaceuticals inc-15.06

SABBY MANAGEMENT, LLC reduced stake in above stock

Sold off

Ticker$ Sold
tonix pharmaceuticals hldg-910,649,000
recon technology ltd-420,408,000
core scientific inc-1,244,120,000
global mofy metaverse ltd-527,607,000
azitra inc-87,390,000
transcode therapeutics inc-228,684,000
scinai immunotherapeutics ltd-131,377,000
pineapple energy inc-231,209,000

SABBY MANAGEMENT, LLC got rid off the above stocks

Sector Distribution

SABBY MANAGEMENT, LLC has about 65.2% of it's holdings in Others sector.

Sector%
Others65.2
Healthcare24.8
Industrials8
Basic Materials1.9

Market Cap. Distribution

SABBY MANAGEMENT, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
UNALLOCATED65.2
NANO-CAP33
MICRO-CAP1.9

Stocks belong to which Index?

About 1.9% of the stocks held by SABBY MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others98.1
RUSSELL 20001.9
Top 5 Winners (%)%
GWAV
greenwave technology
1269.2 %
Top 5 Winners ($)$
GWAV
greenwave technology
376.5 M
Top 5 Losers (%)%
EFTR
effector therapeutics
-83.7 %
APDN
applied dna sciences inc
-68.3 %
AMPG
amplitech group inc
-64.4 %
APVO
aptevo therapeutics inc
-60.0 %
SBFM
sunshine biopharma inc
-53.5 %
Top 5 Losers ($)$
EFTR
effector therapeutics
-522.6 M
APVO
aptevo therapeutics inc
-230.2 M
SONN
sonnet biotherapeutics hldng inc
-189.0 M
NEXI
neximmune inc
-164.9 M
LIPO
lipella pharmaceuticals inc
-125.5 M

SABBY MANAGEMENT, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SABBY MANAGEMENT, LLC

SABBY MANAGEMENT, LLC has 27 stocks in it's portfolio. About 4.1% of the portfolio is in top 10 stocks. EFTR proved to be the most loss making stock for the portfolio. GWAV was the most profitable stock for SABBY MANAGEMENT, LLC last quarter.

Last Reported on: 14 Aug, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions